In clinical trials
Digestive & weight
CagriSema
Evidence
Clinical trials
Class
Combination of an amylin analog and a GLP-1 agonist
KEY TAKEAWAY
CagriSema combines cagrilintide, an amylin analog, with semaglutide, a GLP-1 receptor agonist, in one weekly injection. CagriSema is still being studied in clinical trials. Check the current regulatory status before relying on this entry.
Written by the Veylo editorial team · Updated
November 2026
What it is
Combination of an amylin analog and a GLP-1 agonist
Being studied for
Studied for obesity and type 2 diabetes
Key fact
CagriSema is still being studied in clinical trials. Check the current regulatory status before relying on this entry.
Route
Weekly subcutaneous injection in trials
Evidence strength
Clinical trials
CagriSema combines cagrilintide, an amylin analog, with semaglutide, a GLP-1 receptor agonist, in one weekly injection.
The two drugs act on different appetite pathways, so together they are meant to reduce weight more than either one alone.
CagriSema is still being studied in clinical trials. Check the current regulatory status before relying on this entry.
Studied for obesity and type 2 diabetes.
Nausea, vomiting and constipation were the most common effects in trials.
CagriSema: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.